The immunology of renal cell carcinoma.
Biomarkers, Tumor
Carcinoma, Renal Cell
/ immunology
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Immune Tolerance
Immunotherapy, Adoptive
Inflammation
/ complications
Kidney Neoplasms
/ immunology
Myeloid Cells
/ immunology
T-Lymphocytes
/ immunology
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Journal
Nature reviews. Nephrology
ISSN: 1759-507X
Titre abrégé: Nat Rev Nephrol
Pays: England
ID NLM: 101500081
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
accepted:
22
06
2020
pubmed:
1
8
2020
medline:
30
12
2020
entrez:
1
8
2020
Statut:
ppublish
Résumé
Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises several subtypes with unique characteristics. The most common subtype (~70% of cases) is clear-cell RCC. RCC is considered to be an immunogenic tumour but is known to mediate immune dysfunction in large part by eliciting the infiltration of immune-inhibitory cells, such as regulatory T cells and myeloid-derived suppressor cells, into the tumour microenvironment. Several possible mechanisms have been proposed to explain how these multiple tumour-infiltrating cell types block the development of an effective anti-tumour immune response, including inhibition of the activity of effector T cells and of antigen presenting cells via upregulation of suppressive factors such as checkpoint molecules. Targeting immune suppression using checkpoint inhibition has resulted in clinical responses in some patients with RCC and combinatorial approaches involving checkpoint blockade are now standard of care in patients with advanced RCC. However, a substantial proportion of patients do not benefit from checkpoint blockade. The identification of reliable biomarkers of response to checkpoint blockade is crucial to facilitate improvements in the clinical efficacy of these therapies. In addition, there is a need for the development of other immune-based strategies that address the shortcomings of checkpoint blockade, such as adoptive cell therapies.
Identifiants
pubmed: 32733094
doi: 10.1038/s41581-020-0316-3
pii: 10.1038/s41581-020-0316-3
doi:
Substances chimiques
Biomarkers, Tumor
0
Immune Checkpoint Inhibitors
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
721-735Subventions
Organisme : NCI NIH HHS
ID : R01 CA168488
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA188767
Pays : United States
Références
Wagner, R. P. Anecdotal, historical and critical commentaries on genetics. Rudolph Virchow and the genetic basis of somatic ecology. Genetics 151, 917–920 (1999).
pubmed: 10049910
pmcid: 1460541
Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001).
pubmed: 11229684
Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
pubmed: 21436444
O’Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151–167 (2019).
pubmed: 30523282
Lee, S. & Margolin, K. Cytokines in cancer immunotherapy. Cancers 3, 3856–3893 (2011).
pubmed: 24213115
pmcid: 3763400
Cheever, M. A. & Higano, C. S. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 17, 3520–3526 (2011).
pubmed: 21471425
Hargadon, K. M., Johnson, C. E. & Williams, C. J. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int. Immunopharmacol. 62, 29–39 (2018).
pubmed: 29990692
Conry, R. M., Westbrook, B., McKee, S. & Norwood, T. G. Talimogene laherparepvec: first in class oncolytic virotherapy. Hum. Vaccin. Immunother. 14, 839–846 (2018).
pubmed: 29420123
pmcid: 5893211
Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
pubmed: 8596936
Keir, M. E. et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203, 883–895 (2006).
pubmed: 16606670
pmcid: 2118286
Raedler, L. A. Keytruda (pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma. Am. Health Drug. Benefits 8, 96–100 (2015).
pubmed: 26629272
pmcid: 4665064
Gong, J., Chehrazi-Raffle, A., Reddi, S. & Salgia, R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J. Immunother. Cancer 6, 8 (2018).
pubmed: 29357948
pmcid: 5778665
Amin, A. & Hammers, H. The evolving landscape of immunotherapy-based combinations for frontline treatment of advanced renal cell carcinoma. Front. Immunol. 9, 3120 (2018).
pubmed: 30687324
Escudier, B. Combination therapy as first-line treatment in metastatic renal-cell carcinoma. N. Engl. J. Med. 380, 1176–1178 (2019).
pubmed: 30779526
Cohen, H. T. & McGovern, F. J. Renal-cell carcinoma. N. Engl. J. Med. 353, 2477–2490 (2005).
pubmed: 16339096
Choueiri, T. K. Renal cell carcinoma. Hematol. Oncol. Clin. North. Am. 25, xiii–xiv (2011).
pubmed: 21763960
Linehan, W. M., Srinivasan, R. & Garcia, J. A. Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. Semin. Oncol. 40, 511–520 (2013).
pubmed: 23972715
pmcid: 4165483
Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014).
pubmed: 24487277
pmcid: 4636053
Latif, F. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317–1320 (1993).
pubmed: 8493574
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).
Kaelin, W. G. Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer 8, 865–873 (2008).
pubmed: 18923434
Turajlic, S. et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx Renal. Cell 173, 595–610.e11 (2018).
pubmed: 29656894
pmcid: 5938372
Mitchell, T. J. et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx Renal. Cell 173, 611–623.e17 (2018).
pubmed: 29656891
pmcid: 5927631
Brannon, A. R. et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 1, 152–163 (2010).
pubmed: 20871783
pmcid: 2943630
Beuselinck, B. et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin. Cancer Res. 21, 1329–1339 (2015).
pubmed: 25583177
Beuselinck, B. et al. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. Acta Oncol. 57, 498–508 (2018).
pubmed: 29095068
Verbiest, A. et al. Molecular subtypes of clear cell renal cell carcinoma are associated with outcome during pazopanib therapy in the metastatic setting. Clin. Genitourin. Cancer 16, e605–e612 (2018).
pubmed: 29239846
Cowey, C. L. & Rathmell, W. K. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr. Oncol. Rep. 11, 94–101 (2009).
pubmed: 19216840
pmcid: 2873025
D’Avella, C., Abbosh, P., Pal, S. K. & Geynisman, D. M. Mutations in renal cell carcinoma. Urol. Oncol. https://doi.org/10.1016/j.urolonc.2018.10.027 (2018).
doi: 10.1016/j.urolonc.2018.10.027
pubmed: 30478013
Hsieh, J. J. et al. Renal cell carcinoma. Nat. Rev. Dis. Prim. 3, 17009 (2017).
pubmed: 28276433
Chen, F. et al. Multilevel genomics-based taxonomy of renal cell carcinoma. Cell Rep. 14, 2476–2489 (2016).
pubmed: 26947078
pmcid: 4794376
Durinck, S. et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat. Genet. 47, 13–21 (2015).
pubmed: 25401301
Cancer Genome Atlas Research Network et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N. Engl. J. Med. 374, 135–145 (2016).
Ji, S., Xiong, Y., Zhao, X., Liu, Y. & Yu, L. Q. Effect of the Nrf2-ARE signaling pathway on biological characteristics and sensitivity to sunitinib in renal cell carcinoma. Oncol. Lett. 17, 5175–5186 (2019).
pubmed: 31186733
pmcid: 6507454
Malouf, G. G., Joseph, R. W., Shah, A. Y. & Tannir, N. M. Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities. Clin. Adv. Hematol. Oncol. 15, 409–418 (2017).
pubmed: 28591094
Blankenstein, T., Coulie, P. G., Gilboa, E. & Jaffee, E. M. The determinants of tumour immunogenicity. Nat. Rev. Cancer 12, 307–313 (2012).
pubmed: 22378190
pmcid: 3552609
Kirkwood, J. M. & Ernstoff, M. S. Interferons in the treatment of human cancer. J. Clin. Oncol. 2, 336–352 (1984).
pubmed: 6323641
McDermott, D. F. Immunotherapy of metastatic renal cell carcinoma. Cancer 115, 2298–2305 (2009).
pubmed: 19402060
Kopecky, O. et al. Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal carcinoma. Acta Medica 50, 207–212 (2007).
pubmed: 18254275
Komohara, Y. et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci. 102, 1424–1431 (2011).
pubmed: 21453387
Nakano, O. et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61, 5132–5136 (2001).
pubmed: 11431351
Seliger, B. et al. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin. Cancer Res. 9, 1721–1727 (2003).
pubmed: 12738726
Atkins, D., Ferrone, S., Schmahl, G. E., Storkel, S. & Seliger, B. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J. Urol. 171, 885–889 (2004).
pubmed: 14713847
Dunker, K. et al. Expression and regulation of non-classical HLA-G in renal cell carcinoma. Tissue Antigens 72, 137–148 (2008).
pubmed: 18721274
Alegre, E. et al. Some basic aspects of HLA-G biology. J. Immunol. Res. 2014, 657625 (2014).
pubmed: 24818168
pmcid: 4000973
Kochan, G., Escors, D., Breckpot, K. & Guerrero-Setas, D. Role of non-classical MHC class I molecules in cancer immunosuppression. Oncoimmunology 2, e26491 (2013).
pubmed: 24482746
pmcid: 3894240
Kren, L. et al. HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma. Diagn. Pathol. 7, 58 (2012).
pubmed: 22640987
pmcid: 3408319
Seliger, B. et al. HLA-E expression and its clinical relevance in human renal cell carcinoma. Oncotarget 7, 67360–67372 (2016).
pubmed: 27589686
pmcid: 5341881
Zhang, S. et al. Immune infiltration in renal cell carcinoma. Cancer Sci. 110, 1564–1572 (2019).
pubmed: 30861269
pmcid: 6501001
Choueiri, T. K. et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann. Oncol. 25, 2178–2184 (2014).
pubmed: 25193987
pmcid: 4288138
Chevrier, S. et al. An immune atlas of clear cell renal cell carcinoma. Cell 169, 736–749.e18 (2017).
pubmed: 28475899
pmcid: 5422211
Baine, M. K. et al. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 6, 24990–25002 (2015).
pubmed: 26317902
pmcid: 4694809
Zhang, X. et al. Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma. BMC Cancer 19, 49 (2019).
pubmed: 30630458
pmcid: 6329070
Porta, C. et al. Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. Anticancer. Res. 27, 165–173 (2007).
pubmed: 17352228
Remark, R. et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin. Cancer Res. 19, 4079–4091 (2013).
pubmed: 23785047
Giraldo, N. A. et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. 21, 3031–3040 (2015).
pubmed: 25688160
Finke, J. H. et al. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. J. Immunother. Emphas. Tumor Immunol. 15, 91–104 (1994).
Finke, J. H. et al. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res. 50, 2363–2370 (1990).
pubmed: 2107973
Schoof, D. D. et al. CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. Cell Immunol. 150, 114–123 (1993).
pubmed: 8102084
Angevin, E., Kremer, F., Gaudin, C., Hercend, T. & Triebel, F. Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity. Int. J. Cancer 72, 431–440 (1997).
pubmed: 9247286
Giraldo, N. A. et al. Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin. Cancer Res. 23, 4416–4428 (2017).
pubmed: 28213366
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).
pubmed: 28187290
pmcid: 28187290
Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
pubmed: 25838373
Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015).
pubmed: 4400238
pmcid: 4400238
Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
pubmed: 22437870
pmcid: 4856023
Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069–1086 (2018).
pubmed: 30115704
Khattri, R., Auger, J. A., Griffin, M. D., Sharpe, A. H. & Bluestone, J. A. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J. Immunol. 162, 5784–5791 (1999).
pubmed: 10229811
Paterson, A. M. et al. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J. Exp. Med. 212, 1603–1621 (2015).
pubmed: 26371185
pmcid: 4577848
Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11 3887–3895 (1992).
pubmed: 1396582
pmcid: 556898
Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153–167 (2018).
pubmed: 28990585
Chen, S. et al. Mechanisms regulating PD-L1 expression on tumor and immune cells. J. Immunother. Cancer 7, 305 (2019).
pubmed: 31730010
pmcid: 6858680
Noman, M. Z. et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781–790 (2014).
pubmed: 24778419
pmcid: 4010891
Barsoum, I. B., Smallwood, C. A., Siemens, D. R. & Graham, C. H. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 74, 665–674 (2014).
pubmed: 24336068
Palsson-McDermott, E. M. et al. Pyruvate kinase M2 is required for the expression of the immune checkpoint PD-L1 in immune cells and tumors. Front. Immunol. 8, 1300 (2017).
pubmed: 29081778
pmcid: 5646285
Zhang, C. et al. TFEB mediates immune evasion and resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1. Clin. Cancer Res. 25, 6827–6838 (2019).
pubmed: 31383732
Lu, D. et al. Beyond T cells: understanding the role of PD-1/PD-L1 in tumor-associated macrophages. J. Immunol. Res. 2019, 1919082 (2019).
pubmed: 31781673
pmcid: 6875348
Tatsumi, T. et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J. Exp. Med. 196, 619–628 (2002).
pubmed: 12208877
pmcid: 2193999
Tatsumi, T. et al. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin. Cancer Res. 9, 947–954 (2003).
pubmed: 12631591
Li, L. et al. Skewed T-helper (Th)1/2- and Th17/T regulatory cell balances in patients with renal cell carcinoma. Mol. Med. Rep. 11, 947–953 (2015).
pubmed: 25352158
DeNardo, D. G. et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16, 91–102 (2009).
pubmed: 19647220
pmcid: 2778576
Abel, A. M., Yang, C., Thakar, M. S. & Malarkannan, S. Natural killer cells: development, maturation, and clinical utilization. Front. Immunol. 9, 1869 (2018).
pubmed: 30150991
pmcid: 6099181
Cozar, J. M. et al. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol. Immunother. 54, 858–866 (2005).
pubmed: 15887015
Schleypen, J. S. et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin. Cancer Res. 12, 718–725 (2006).
pubmed: 16467081
Eckl, J. et al. Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J. Mol. Med. 90, 55–66 (2012).
pubmed: 21870102
Donskov, F. et al. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br. J. Cancer 87, 194–201 (2002).
pubmed: 12107842
pmcid: 2376103
Toliou, T., Stravoravdi, P., Polyzonis, M. & Vakalikos, J. Natural killer cell activation after interferon administration in patients with metastatic renal cell carcinoma: an ultrastructural and immunohistochemical study. Eur. Urol. 29, 252–256 (1996).
pubmed: 8647158
Trotta, A. M. et al. Mutated von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity. J. Exp. Clin. Cancer Res. 37, 297 (2018).
pubmed: 30514329
pmcid: 6278085
Engblom, C., Pfirschke, C. & Pittet, M. J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16, 447–462 (2016).
pubmed: 27339708
Soos, T. J. et al. CX3CR1+ interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int. 70, 591–596 (2006).
pubmed: 16760907
Toma, M. et al. Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis. Oncoimmunology 4, e1008342 (2015).
pubmed: 26155414
pmcid: 4485722
Hamada, I. et al. Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer. Res. 22, 4281–4284 (2002).
pubmed: 12553070
Toge, H., Inagaki, T., Kojimoto, Y., Shinka, T. & Hara, I. Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages. Int. J. Urol. 16, 801–807 (2009).
pubmed: 19811548
Kovaleva, O. V., Samoilova, D. V., Shitova, M. S. & Gratchev, A. Tumor associated macrophages in kidney cancer. Anal. Cell Pathol. 2016, 9307549 (2016).
Roumenina, L. T. et al. Tumor cells hijack macrophage-produced complement C1q to promote tumor growth. Cancer Immunol. Res. 7, 1091–1105 (2019).
pubmed: 31164356
Ko, J. S. et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 70, 3526–3536 (2010).
pubmed: 20406969
pmcid: 3426924
Ko, J. S. et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15, 2148–2157 (2009).
pubmed: 19276286
Najjar, Y. G. et al. Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL1β, IL8, CXCL5, and Mip-1α. Clin. Cancer Res. 23, 2346–2355 (2017).
pubmed: 27799249
Diaz-Montero, C. M. et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49–59 (2009).
pubmed: 18446337
Peranzoni, E. et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22, 238–244 (2010).
pubmed: 20171075
Tannenbaum, C. S. et al. Mediators of inflammation-driven expansion, trafficking, and function of tumor-infiltrating MDSCs. Cancer Immunol. Res. 7, 1687–1699 (2019).
pubmed: 31439615
pmcid: 6774821
Feng, S. et al. Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers. Proc. Natl Acad. Sci. USA 115, 10094–10099 (2018).
pubmed: 30232256
Najjar, Y. G. & Finke, J. H. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front. Oncol. 3, 49 (2013).
pubmed: 23508517
pmcid: 3597982
Finke, J. et al. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 11, 856–861 (2011).
pubmed: 21315783
Corzo, C. A. et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 182, 5693–5701 (2009).
pubmed: 19380816
pmcid: 2833019
Serafini, P., Mgebroff, S., Noonan, K. & Borrello, I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68, 5439–5449 (2008).
pubmed: 18593947
pmcid: 2887390
Rodriguez, P. C., Quiceno, D. G. & Ochoa, A. C. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109, 1568–1573 (2007).
pubmed: 17023580
pmcid: 1794048
Rodriguez, P. C. et al. Regulation of T cell receptor CD3ζ chain expression by L-arginine. J. Biol. Chem. 277, 21123–21129 (2002).
pubmed: 11950832
Rodriguez, P. C. & Ochoa, A. C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222, 180–191 (2008).
pubmed: 18364002
pmcid: 3546504
Ostrand-Rosenberg, S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 59, 1593–1600 (2010).
pubmed: 20414655
pmcid: 3706261
Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162–174 (2009).
pubmed: 19197294
pmcid: 2828349
Condamine, T., Ramachandran, I., Youn, J. I. & Gabrilovich, D. I. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu. Rev. Med. 66, 97–110 (2015).
pubmed: 25341012
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
pubmed: 21376230
pmcid: 21376230
Shalapour, S. & Karin, M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J. Clin. Invest. 125, 3347–3355 (2015).
pubmed: 26325032
pmcid: 4588298
Petrella, B. L. & Vincenti, M. P. Interleukin-1β mediates metalloproteinase-dependent renal cell carcinoma tumor cell invasion through the activation of CCAAT enhancer binding protein β. Cancer Med. 1, 17–27 (2012).
pubmed: 23342250
pmcid: 3544428
Chittezhath, M. et al. Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. Immunity 41, 815–829 (2014).
pubmed: 25453823
Kaminska, K., Czarnecka, A. M., Escudier, B., Lian, F. & Szczylik, C. Interleukin-6 as an emerging regulator of renal cell cancer. Urol. Oncol. 33, 476–485 (2015).
pubmed: 26296264
Fu, Q. et al. Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis. Br. J. Cancer 113, 1581–1589 (2015).
pubmed: 26554658
pmcid: 4705889
Harrison, M. L. et al. Tumor necrosis factor α as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J. Clin. Oncol. 25, 4542–4549 (2007).
pubmed: 17925549
Ho, M. Y. et al. TNF-α induces epithelial-mesenchymal transition of renal cell carcinoma cells via a GSK3β-dependent mechanism. Mol. Cancer Res. 10, 1109–1119 (2012).
pubmed: 22707636
Sun, K. H. et al. TNF-α augments CXCR2 and CXCR3 to promote progression of renal cell carcinoma. J. Cell Mol. Med. 20, 2020–2028 (2016).
pubmed: 27297979
pmcid: 5082409
Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436–444 (2008).
Elinav, E. et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 13, 759–771 (2013).
pubmed: 24154716
Triner, D. & Shah, Y. M. Hypoxia-inducible factors: a central link between inflammation and cancer. J. Clin. Invest. 126, 3689–3698 (2016).
pubmed: 27525434
pmcid: 5096825
Reuter, S., Gupta, S. C., Chaturvedi, M. M. & Aggarwal, B. B. Oxidative stress, inflammation, and cancer: how are they linked? Free. Radic. Biol. Med. 49, 1603–1616 (2010).
pubmed: 20840865
pmcid: 2990475
Li, Y., Patel, S. P., Roszik, J. & Qin, Y. Hypoxia-driven immunosuppressive metabolites in the tumor microenvironment: new approaches for combinational immunotherapy. Front. Immunol. 9, 1591 (2018).
pubmed: 30061885
pmcid: 6054965
Fahey, E. & Doyle, S. L. IL-1 family cytokine regulation of vascular permeability and angiogenesis. Front. Immunol. 10, 1426 (2019).
pubmed: 31293586
pmcid: 6603210
Johnson, D. E., O’Keefe, R. A. & Grandis, J. R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234–248 (2018).
pubmed: 29405201
pmcid: 5858971
Ward, P. S. & Thompson, C. B. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21, 297–308 (2012).
pubmed: 22439925
pmcid: 3311998
Kim, J. Regulation of immune cell functions by metabolic reprogramming. J. Immunol. Res. 2018, 8605471 (2018).
pubmed: 29651445
pmcid: 5831954
Li, H. et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat. Commun. 10, 4346 (2019).
pubmed: 31554815
pmcid: 6761178
Lameirinhas, A., Miranda-Goncalves, V., Henrique, R. & Jeronimo, C. The complex interplay between metabolic reprogramming and epigenetic alterations in renal cell carcinoma. Genes 10, 264 (2019).
pmcid: 6523766
Wettersten, H. I. et al. Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis. Cancer Res. 75, 2541–2552 (2015).
pubmed: 25952651
pmcid: 4470795
Lucarelli, G. et al. Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. Urol. Oncol. 35, 461.e15–461.e27 (2017).
Li, L. & Kaelin, W. G. Jr New insights into the biology of renal cell carcinoma. Hematol. Oncol. Clin. North. Am. 25, 667–686 (2011).
pubmed: 21763962
pmcid: 3161447
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
pubmed: 20525992
pmcid: 3549297
Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).
pubmed: 21639810
Yang, J. C. et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30, 825–830 (2007).
pubmed: 18049334
pmcid: 2134980
Hammers, H. J. et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J. Clin. Oncol. 35, 3851–3858 (2017).
pubmed: 28678668
pmcid: 7587408
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
pubmed: 29562145
pmcid: 5972549
Cella, D. et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 20, 297–310 (2019).
pubmed: 30658932
pmcid: 6701190
Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167–3175 (2010).
pubmed: 20516446
pmcid: 4834717
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
pubmed: 3544539
pmcid: 3544539
Motzer, R. J. et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J. Clin. Oncol. 33, 1430–1437 (2015).
pubmed: 25452452
Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
pubmed: 26406148
pmcid: 5719487
Choueiri, T. K. et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin. Cancer Res. 22, 5461–5471 (2016).
pubmed: 27169994
pmcid: 5106340
McDermott, D. F. et al. Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427 [abstract]. J. Clin. Oncol. 36 (Suppl. 15), 4500 (2018).
McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749–757 (2018).
pubmed: 29867230
pmcid: 6721896
Vaishampayan, U. et al. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. J. Immunother. Cancer 7, 275 (2019).
pubmed: 31651359
pmcid: 6813090
Takyar, S., Diaz, J., Sehgal, M., Sapunar, F. & Pandha, H. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials. Anticancer Drugs 27, 383–397 (2016).
pubmed: 26886011
Duran, I. et al. Resistance to targeted therapies in renal cancer: the importance of changing the mechanism of action. Target. Oncol. 12, 19–35 (2017).
pubmed: 27844272
Almand, B. et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166, 678–689 (2001).
pubmed: 11123353
Yang, J., Yan, J. & Liu, B. Targeting VEGF/VEGFR to modulate antitumor immunity. Front. Immunol. 9, 978 (2018).
pubmed: 29774034
pmcid: 5943566
Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103–2111 (2007).
pubmed: 18156031
Rini, B. I. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28, 2137–2143 (2010).
pubmed: 20368558
pmcid: 2860433
Considine, B. & Hurwitz, M. E. Current status and future directions of immunotherapy in renal cell carcinoma. Curr. Oncol. Rep. 21, 34 (2019).
pubmed: 30848378
Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019).
pubmed: 30779531
pmcid: 6716603
Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019).
pubmed: 30779529
de Velasco, G. et al. Comprehensive analysis of survival outcomes in non-clear cell renal cell carcinoma patients treated in clinical trials. Clin. Genitourin. Cancer 15, 652–660.e1 (2017).
pubmed: 28410911
Koshkin, V. S. et al. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J. Immunother. Cancer 6, 9 (2018).
pubmed: 29378660
pmcid: 5789686
McKay, R. R. et al. The clinical activity of PD-1/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma. Cancer Immunol. Res. 6, 758–765 (2018).
pubmed: 29748390
pmcid: 6712567
Lee, J.-L. et al. KEYNOTE-427 cohort B: first-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC) [abstract]. J. Clin. Oncol. 37(Suppl. 15), 4569 (2019).
Ravaud, A. et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N. Engl. J. Med. 375, 2246–2254 (2016).
pubmed: 27718781
Wang, J. et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat. Med. 25, 656–666 (2019).
pubmed: 30833750
pmcid: 30833750
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03665285 (2019).
Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847–856 (2015).
pubmed: 25695955
Basu, A., Yearley, J. H., Annamalai, L., Pryzbycin, C. & Rini, B. Association of PD-L1, PD-L2, and immune response markers in matched renal clear cell carcinoma primary and metastatic tissue specimens. Am. J. Clin. Pathol. 151, 217–225 (2019).
pubmed: 30346474
Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
pubmed: 25409260
pmcid: 4315319
Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
pubmed: 25765070
pmcid: 4993154
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
pubmed: 23945592
pmcid: 23945592
Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).
pubmed: 5576142
pmcid: 5576142
Lemery, S., Keegan, P., Pazdur, R. & First, F. D. A. Approval agnostic of cancer site – when a biomarker defines the indication. N. Engl. J. Med. 377, 1409–1412 (2017).
pubmed: 29020592
Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009–1021 (2017).
pubmed: 28694034
Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).
pubmed: 27433843
pmcid: 5007206
Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7, 188–201 (2017).
pubmed: 27903500
Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554.e12 (2016).
pubmed: 27912061
pmcid: 5385895
Rini., B. et al. Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC) [abstract]. Ann. Oncol. 29, viii724–viii725 (2018).
Kim, H. Y. et al. Discovery of potential biomarkers in human melanoma cells with different metastatic potential by metabolic and lipidomic profiling. Sci. Rep. 7, 8864 (2017).
pubmed: 28821754
pmcid: 5562697
Tanimine, N., Turka, L. A. & Priyadharshini, B. Navigating T-cell immunometabolism in transplant. Transplantation 102, 230–239 (2018).
pubmed: 28930796
pmcid: 5790597
Mock, A. et al. Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers. Cancer Immunol. Immunother. 68, 2005–2014 (2019).
pubmed: 31701161
Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).
pubmed: 29097494
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A. & Dudley, M. E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8, 299–308 (2008).
pubmed: 18354418
pmcid: 2553205
Rosenberg, S. A. et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst. 85, 622–632 (1993).
pubmed: 8468720
Figlin, R. A. et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J. Clin. Oncol. 17, 2521–2529 (1999).
pubmed: 10561318
Andersen, R. et al. T-cell responses in the microenvironment of primary renal cell carcinoma–implications for adoptive cell therapy. Cancer Immunol. Res. 6, 222–235 (2018).
pubmed: 29301752
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02830724 (2020).
Shaffer, D. R. et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 117, 4304–4314 (2011).
pubmed: 21304103
pmcid: 3087480
Li, H. et al. Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice. Cell Death Dis. 9, 177 (2018).
pubmed: 29415996
pmcid: 5833445
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03618381 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03696030 (2020).
Zhang, J. & Wang, L. The emerging world of TCR-T cell trials against cancer: a systematic review. Technol. Cancer Res. Treat. 18, 1533033819831068 (2019).
pubmed: 30798772
pmcid: 6391541
Habif, G., Crinier, A., Andre, P., Vivier, E. & Narni-Mancinelli, E. Targeting natural killer cells in solid tumors. Cell Mol. Immunol. 16, 415–422 (2019).
pubmed: 30911118
pmcid: 6474204
Burger, M. C. et al. CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy. Front. Immunol. 10, 2683 (2019).
pubmed: 31798595
pmcid: 6868035
Zhang, Q. et al. Synergistic effects of cabozantinib and EGFR-specific CAR-NK-92 cells in renal cell carcinoma. J. Immunol. Res. 2017, 6915912 (2017).
pubmed: 29423418
pmcid: 5750507
Boissel, L. et al. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2, e26527 (2013).
pubmed: 24404423
pmcid: 3881109
Romanski, A. et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J. Cell Mol. Med. 20, 1287–1294 (2016).
pubmed: 27008316
pmcid: 4929308
Rini, B. I. et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393, 2404–2415 (2019).
pubmed: 31079938
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02811861 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03141177 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03055013 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03138512 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03142334 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03024996 (2020).